Interim analyses
We will perform interim analyses if the 5-year IBTR is > 5% in patients who received only low-dose tamoxifen or only underwent RT; furthermore, we will discontinue this non-inferiority trial according to the assumption that the cumulative incidence of IBTR in the experimental (tamoxifen) or control groups (RT) was 6% at 7 years.